Home
Life Sciences
Pharmaceutical
The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets

Pharmaceutical

Summary

Table of Contents

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets

Publication date: October 2009

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

At their most basic level, wellness programs represent an attempt to encourage good health and thereby decrease utilization of health care products and services. They have evolved out of necessity from the current U.S. health care system, in response to a variety of factors including continually rising costs of care and declining quality of life.

A Comprehensive Look at the 'Wellness' Industry

Utilization of wellness programs in the United States has experienced strong recent growth this is expected to continue through the forecast period. As more people participate in wellness programs, their usage of various health care products and services will be affected, as well the revenues of wellness program providers.
This report looks at the emerging wellness industry and estimates the market for wellness related products and services. This portion of the report examines:

Drivers of Wellness Services

Utilization Statistics

Major Companies and Offerings

Current Wellness Program Market Size

Innovative Approaches

Results of Programs

General Trends (Weak U.S. Economy, Postponing of Retirement, EMR, Rising Interest in Anti-Aging)

Industry Trends (Internet-Based Wellness Programs, Usage of Financial Incentives, Emergence of Retail Clinics)

A Report No Pharmaceutical, Device or Testing Product Marketer Should Be Without

If wellness programs are effective, there should be an impact on all healthcare industries: pharmaceuticals, devices and diagnostics. Positive impact for some, negative for others. As part of Kalorama's unique analysis on this topic, this report also takes a look at how the popularity of wellness programs will effect other markets. The report estimates the positive or negative sales impact of wellness programs upon established U.S. markets for various health care products and services including:

Allergy Medicines

Cholesterol Reducers

Diabetes Drugs

Gastrointestinal Medications/Proton Pump Inhibitors

Hypertension Medicines

Over-the-Counter (OTC) Medicines

Influenza Vaccines

Cervical Cancer Vaccines

Diagnostic Tests

Cardiovascular, Gastric Banding, and other Devices

Surgeries,

Imaging

Other Medical Services

Within each of these market segments, products, services and/or sub-segments were selected that will particularly be affected by wellness programs. Products, services and/or sub-segments that are not expected to be significantly impacted were not included.

Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are provided for the historic 2004 - 2008 period and forecasts are provided through 2013. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

Because this industry is extremely fragmented, with thousands of providers offering many different types of programs tailored to different patient populations, an effort was made to include a broad representation of groups. Companies profiled include:

Aetna

Azente Wellness

Cigna

Coleman Wellness Solutions

ConnectiCare

Corporate Wellness

ConvergenceHealth

CuraLinc Healthcare

Dynamic Wellness

Employee Health Management Systems

Hawaii Medical Assurance Association

incentaHEALTH

KC Wellness

Kersh Risk Management.

Kronos Optimal Health Company

Mayo Clinic Health Solutions

MedHealth Solutions

MO Healthnet

Multicare Health System

National Corporate Wellness.

Nuvita

PATH

Physicians Medical Group of Santa Cruz County

Preventure

Professional Health Services

Pure Wellness

Summit Health..

San Francisco Wellness Initiative

US Corporate Wellness

Wellness Advantage

Wellness Corporate Solutions

Wellness Works

Wyoming State Wellness Program

Pharmaceutical Industry in the United States

CHAPTER ONE: EXECUTIVE SUMMARY: Wellness Programs And Their Impact on U.S. Healthcare Markets; Scope and Methodology; Introduction; Key Healthcare Markets Impacted by Wellness Programs; Wellness Programs market
CHAPTER TWO: INTRODUCTION: The U.S. Health Care System Today; Costs Related To A Lack Of Wellness; Wellness Programs
CHAPTER THREE: KEY HEALTH CARE MARKETS IMPACTED BY WELLNESS PROGRAMS: Prescription Medicines; Non-Prescription Medicines; Adult Vaccines; Clinical Diagnostic Tests; Medical Devices; Medical Services; Total Effects of Wellness Programs
CHAPTER FOUR: WELLNESS PROGRAMS MARKET: Program Provider Revenues; Issues and Trends; Weak U.S. Economy; Postponing of Retirement; Internet-Based Wellness Programs; Usage of Financial Incentives; Electronic Medical Records; Declining Public Health; Pressure to Democratize Wellness; Rising Interest in Anti-Aging; Emergence of Retail Clinics
CHAPTER FIVE: PROVIDER PROFILES: Aetna; Azente Wellness; Cigna; Coleman Wellness Solutions; ConnectiCare; Corporate Wellness; ConvergenceHealth; CuraLinc Healthcare; Dynamic Wellness; Employee Health Management Systems; Hawaii Medical Assurance Association; incentaHEALTH; Infinite Wellness Solutions; KC Wellness; Kersh Risk Management; Kronos Optimal Health Company; Mayo Clinic Health Solutions; MedHealth Solutions; MO Healthnet; Multicare Health System; National Corporate Wellness; Nuvita; PATH; Physicians Medical Group of Santa Cruz County; Preventure; Professional Health Services; Pure Wellness; San Francisco Wellness Initiative; Summit Health; US Corporate Wellness; Wellness Advantage; Wellness Corporate Solutions; Wellness Works
TABLE OF EXHIBITS
CHAPTER TWO: INTRODUCTION: Figure 2-1: National Health Expenditures (NHE) and NHE as a Percent of GDP, 1980-2017; Figure 2-2: Premium Increases vs. Increases in Workers Earnings and Prices, 1989-2008; Figure 2-3: Consumer Out of Pocket Expenditures per Worker, 2003-2013; Figure 2-3: Unnecessary Deaths Resulting From Variations in Health Care Quality, 2008; Table 2-1: U.S. Health Care Coverage by State, 2009; Figure 2-4: U.S. Costs for Illness Treatment and Prevention, 1980-2017; Table 2-2: Obesity in the United States, 1980-2013; Table 2-3: Common Diseases of the Lungs, 2009
CHAPTER THREE KEY HEALTH CARE MARKETS IMPACTED BY WELLNESS PROGRAMS: Table 3-1: Effect of Wellness Programs on Key U.S. Health care Markets; Table 3-2: U.S. Rx Allergy Drug Sales and Impact of Wellness Programs, 2004 -2013; Table 3-3: Types of Cholesterol Reducing Medications and Their Effect; Table 3-4: U.S. Rx Cholesterol Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-5: U.S. Diabetes Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-6: U.S. Rx Gastrointestinal/PPI Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-7: U.S. Rx Hypertension Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-8: Total U.S. Rx Drug Sales and Impact of Wellness Programs on Selected Drug Groups, 2004-2013; Figure 3-1: Impact of Wellness Programs on Selected Rx Drug Groups, 2004-2013; Table 3-9: U.S. OTC Allergy Remedy Sales and Impact of Wellness Programs, 2004-2013; Table 3-10: U.S. Blood Glucose Testing Sales and Impact of Wellness Programs, 2004-2013; Table 3-11: U.S. OTC Gastrointestinal Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-12: U.S. OTC Smoking Cessation Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-13: U.S. OTC Weight Loss Drug Sales and Impact of Wellness Programs, 2004-2013; Table 3-14: Total U.S. OTC Drug Sales and Impact of Wellness Programs on Selected Drug Groups, 2004-2013; Figure 3-2: Impact of Wellness Programs on Selected OTC Drug Groups, 2004-2013; Table 3-15: U.S. Influenza Vaccine Sales and Impact of Wellness Progress 2004-2013; Table 3-16: U.S. Cervical Cancer Vaccine Sales and Impact of Wellness Programs, 2004-2013; Table 3-17: U.S. Vaccine Sales and Impact of Wellness Programs, 2004-2013; Figure 3-3: Impact of Wellness Programs on Vaccine Sales, 2004-2013; Table 3-18: U.S. POC Test Sales and Impact of Wellness Programs, 2004-2013; Table 3-19: U.S. Clinical Chemistry and Immunoassay Test Sales and Impact of Wellness Programs, 2004-2013; Table 3-20: U.S. Clinical Test Sales and Impact of Wellness Programs, 2004-2013; Figure 3-4: Impact of Wellness Programs on Clinical Diagnostic Tests, 2004-2013; Table 3-21: U.S. Cardiovascular Device Sales and Impact of Wellness Programs on Selected Drug Groups, 2004-2013; Table 3-22: U.S. Gastric Banding Device Sales and Impact of Wellness Programs, 2004-2013; Table 3-23: Selected U.S. Medical Device Sales and Impact of Wellness Programs, 2004-2013; Figure 3-5: Impact of Wellness Programs on Medical Devices, 2004-2013; Table 3-24: U.S. Surgical Intervention Revenues and Impact of Wellness Programs, 2004-2013; Table 3-25: U.S. Medical Imaging Revenues and Impact of Wellness Programs, 2004-2013; Table 3-26: Selected U.S. Medical Service Revenues and Impact of Wellness Programs, 2004-2013; Figure 3-6: Impact of Wellness Programs on Medical Services, 2004-2013; Table 3-27: Total U.S. Health Care Market Revenues, 2004-2013,; Figure 3-7: Total U.S. Health Care Market, by Segment, 2008; Figure 3-8: Total U.S. Health Care Market, by Segment, 2013; Table 3-28: U.S. Health Care Revenues Lost or Gained from Wellness Programs, 2004-2013; Figure 3-9: U.S. Health Care Revenues Lost or Gained from Wellness Programs, by Segment, 2004-2013; Figure 3-10: Total Effect on U.S. Health Care Revenues Lost or Gained from Wellness Programs, by Segment, 2004 - 2013; Table 3-29: Growth of Total U.S. Health Care Revenues and Revenues Lost or Gained from Wellness Programs, 2004-2013; Figure 3-11: Annual U.S. Health Care Industry Growth vs. Growth of Lost or Gained Revenues from Wellness Programs, by Segment, 2004-2008; Figure 3-12: Annual U.S. Health Care Industry Growth vs. Growth of Lost or Gained Revenues from Wellness Programs, by Segment, 2008-2013
CHAPTER FOUR: WELLNESS PROGRAMS MARKET: Table 4-1: U.S. Wellness Programs Market, 2004-2013; Figure 4-1: U.S. Spending on Wellness Programs as a Proportion of Total Spending on Health Care Prevention, 2004-2013; Table 4-2: Effect on Wellness Programs of Industry Trends
CHAPTER FIVE: PROVIDER PROFILES: Table 5-1: Aetna’s Revnue and Net Earnings, 2006-2008; Table 5-2: Cigna’s Revnue and Net Earnings, 2006-2008

Talk to Robyn

00 1 718 213 49 04

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Pharmaceutical Industry in the United States : Latest Reports

Vaccines - Americas

$ 5 174
Industry report
March 2012
by Global Research & Data Services

This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for vaccines in American markets. The analyses provide essential market information ...

Global Human Vaccines Industry

$ 4 500
Industry report
March 2012
by Global Industry Analyst

This report analyzes the worldwide markets for Prophylatic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines. The report provides ...

Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts)

$ 2 500
Industry report
February 2012
by Kalorama Information

The considerable revenue growth in the vaccine market over the past ten years suggests the amount of vaccine production and the techniques of vaccine production will need to adapt to match a revived industry. ...

Vaccines - Top 5 American Markets

March 2012 $ 2 514

Vaccines - Georgia

March 2012 $ 652

Vaccines - United States

March 2012 $ 652

The Pharmaceutical Market: Usa

February 2012 $ 1 085

Insulin Delivery Systems Market Forecast T ...

February 2012 $ 1 400

Disease And Therapy Review: Hepatitis B

February 2012 $ 995

Pancreatitis Global Clinical Trials Review ...

January 2012 $ 1 000

More Reports:

Pharmaceutical in China (231)

Pharmaceutical in France (335)

Pharmaceutical in Germany (347)

Pharmaceutical in Italy (340)

Pharmaceutical in Japan (431)

Pharmaceutical in Spain (330)

Pharmaceut... in the United Kingdom (402)

Pharmaceut... in the United States (1292)

Company Reports

GlaxoSmithKline P.L.C.

GlaxoSmithKline PLC

Sanofi-Aventis Senegal

Johnson And Johnson

Novartis Inc.

AstraZeneca PLC

Pfizer Inc.

Amgen Inc.

Emergent BioSolutions Inc.

Eli Lilly And Co.

Pharmaceutical Industry in the United States : Latest Downloads

U.S. Pharmaceutical Industry

Industry report
May 2012
31 pages
by Corporation

... Severe uncontrolled asthma periostin level zelboraf metastatic melanoma braf v600e mutation t-dm1 metastatic breast cancer her2 expression level mericitabine and danoprevir hepatitis c hcv ...

Malaria Industry (malaria, anemia) in The United States and Mali

Industry report
April 2012
9 pages

... Population of african children with manifestations of severe malaria and uncomplicated malaria, as well as healthy controls. Materials and methods study site and enrollment. Serum was obtained from 776 malian ...

Pharmaceutical Market in Egypt and The United States

Industry report
April 2012
37 pages

... Infection is higher in those with cirrhosis than in those with chronic hepatitis. Hcv is the dominant viral cause of hcc and it contributed to the increasing incidence of hcc during the past 2 decades ...